Novartis grabs kidney drug developer Regulus in $1.7bn deal
Novartis has reached an settlement to purchase Regulus Therapeutics and its experimental remedy for autosomal dominant polycystic kidney illness (ADPKD) ...
Novartis has reached an settlement to purchase Regulus Therapeutics and its experimental remedy for autosomal dominant polycystic kidney illness (ADPKD) ...
Specialty pharmaceutical distributor Morris & Dickson is partnering with Mark Cuban Price Plus Drug Firm (MCCPDC) and the Price Plus Market ...
The massive income alternative stemming from latest success of GLP-1 medication is not only for the pharmaceutical firms. Is your ...
Johnson & Johnson’s pharmaceutical arm, Janssen, has shared early preclinical findings on its new antiviral drug, JNJ-9676, which exhibits promise ...
For 3 weeks final Might, workers of the AI big Nvidia and Recursion Prescription drugs slept on the ground of ...
Takeda's Adcetris has grow to be the primary drug really helpful for routine NHS use as a remedy for beforehand ...
Textual content signal displaying Trade Information. Enterprise photograph textual content delivering information to most people or a goal public | ...
Researchers within the US have devised a brand new depot system that would present months and even years of supply ...
Oxford BioTherapeutics (OBT) has lined up one other large pharma accomplice for its drug discovery platform, agreeing to work with ...
Eisai can have an unprecedented third try to persuade consultants at UK medicines cost-effectiveness assessor NICE that the NHS ought ...
Welcome to The Auto Newspaper, a premier online destination for insightful content and in-depth analysis across a wide range of sectors. Our goal is to provide you with timely, relevant, and expert-driven articles that inform, educate, and inspire action in the ever-evolving world of business, technology, finance, and beyond.
© 2025 https://www.theautonewspaper.com/- All Rights Reserved